Seattle doctor developing treatment for sickest COVID-19 patients

SEATTLE — The fatality rate for COVID-19 victims on ventilators has been 50% or higher.

So, at Atossa Therapeutics in Seattle, Dr. Steven Quay is getting a drug combination ready for a clinical trial in a hard-hit hospital back east.

“There’s a side port on the ventilator where you can put medication for these patients … basically they can breathe a mist while they are on the ventilator and the goal is to get them off the ventilator and once you are off the ventilator you’ll have an improved clinical course.

Quay is CEO of Seattle’s Atossa Therapeutics. He’s says he’s invented seven FDA approved drugs for other illnesses.

Called H-NAC, the drug would put a coating over the parts of the virus that help them replicate so quickly, rendering it ineffective, similar to what a vaccine does.

“We want to teach the immune system to coat the virus with antibodies, I’m coating the virus … with these two already FDA approved drugs,” he said.

Source:
https://www.kiro7.com/news/local/seattle-doctor-developing-treatment-sickest-covid-19-patients/OO4DJZ7BHBCUPI5FRPB3ZMW5KQ/

About Dr. Quay

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and COVID-19 therapeutics.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow in the Chemistry Department at MIT with Nobel Laureate H. Gobind Khorana, and a resident at the Harvard-MGH Hospital, and spent almost a decade on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times.

He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passions are big medical problems: stopping the COVID-19 pandemic and preventing the two million breast cancers in the world each year.

The COVID-19 HOPE Clinical Trial​